Changes in health and disease of the metalloprotease that cleaves von Willebrand factor

Blood

Volumn 98, Issue 9, 2001, Pages 2730-2735

  Mannucci, Pier O ^a,b   Canciani, Maria Teresa ^b   Forza, Ileana ^a   Lussana, Federico ^a   Lattuada, Antonella ^b   Rossi, Edoardo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; METALLOPROTEINASE; VON WILLEBRAND FACTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NEWBORN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN DEGRADATION; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA;

EID: 0035525768     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.9.2730     Document Type: Article

References (26)

1. McCrae KR, Cines DB. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000;2126-2137.
2. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya T, Kaketani K. Immunohistochemistry of vascular lesions in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985;38:469-479.
3. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int. 1987;32:292-308.
4. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097-3103.
5. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor - cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med. 1998;339:1578-1584.
6. Tsai H-M, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594.
7. Furlan M, Robles R, Lämmle BL. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234.
8. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235-4244.
9. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand disease. Proc Natl Acad Sci U S A. 1990;87:6306-6310.
10. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986;46:185-190.
11. Tsai HM, Nagel RL, Hatcher VB, Sussman II. Multimeric composition of endothelial cell-derived von Willebrand factor. Blood. 1989;73:2074-2076.
12. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432-1435.
13. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (VWF) multimers and unusually large VWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456-1461.
14. Gerritsen H, Turecek P, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (VWF)-cleaving protease based on decreased collagen binding affinity of degraded VWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386-1389.
15. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood. 1982;59:1272-1278.
16. Englender T, Lattuada A, Mannucci PM, Sadler JE, Inbal A. Analysis of Arg834GIn and VaI902GIu type 2A von Willebrand disease mutations: studies with recombinant von Willebrand factor and correlation with patient characteristics. Blood. 1996;87:2788-2794.
17. Mannucci PM, Lombardi R, Castaman G, et al. Von Willebrand disease "Vicenza" with larger that normal (supranormal) von Willebrand factor multimers. Blood. 1988;71:947-952.
18. Favatoro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II von Willebrand's disease. Blood Coagul Fibrinolysis. 1991;2:285-291.
19. Tsai H-M, Rice L, Sarode R, Chow T, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med. 2000;132:794-799.
20. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773-1777.
21. Laurence J. Pathological and therapeutic distinctions in HUS/TTP [abstract]. Lancet. 2000;355:4971.
22. Tsai H-M, Chandler WL, Sarode R, et at. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli 0157: H7-associated hemolylic uremic syndrome. Pediatr Res. 2001;49:653-659.
23. van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood. 1999;93:3798-3802.
24. Oleksowicz L, Bhagwati N, DeLeon-Fernandez M, Deficient activity of von Willebrand factor cleaving protease in patients with disseminated malignancies. Cancer Res. 1999;59:2244-2250.
25. Fontana S, Gerritsen HE, Kremer Hovinga J, Furlan M, Lammle B. Microangiophatic hemolytic anemia in metastasizing malignant tumors is not associated with a severe deficiency of the von Willebrand factor cleaving protease. Br J Haematol. 2001;113:100-102.
26. Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999;81:8-13.